Market Newsdesk

GONZALES, La., May 14, 2025 (GLOBE NEWSWIRE) — Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the “Company”) announced today that its Board of Directors has declared a quarterly cash dividend on its Series A common stock of $0.08 per share to be paid on July 3, 2025 to stockholders of record at the close of business on June 13, 2025.

About Crown Crafts, Inc.

Crown Crafts, Inc. designs, markets and distributes infant, toddler and juvenile consumer products. Founded in 1957, Crown Crafts is one of America’s largest producers of infant and toddler bedding and blankets, bibs, diaper bags, disposable products and developmental toys. The Company operates through its wholly owned subsidiaries, Sassy Baby, Inc. and NoJo Baby & Kids, Inc., which market a variety of infant, toddler and juvenile products under Company-owned trademarks, as well as licensed collections and exclusive private label programs. Sales are made directly to retailers such as mass merchants, large chain stores and juvenile specialty stores. For more information, visit the Company’s website at www.crowncrafts.com.

Forward-Looking Statements

The foregoing contains forward-looking statements within the meaning of the Securities Act of 1933, the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such statements are based upon management’s current expectations, projections, estimates and assumptions. Words such as “expects,” “believes,” “anticipates” and variations of such words and similar expressions identify such forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties that may cause future results to differ materially from those suggested by the forward-looking statements. These risks include, among others, general economic conditions, including changes in interest rates, in the overall level of consumer spending and in the price of oil, cotton and other raw materials used in the Company’s products, changing competition, changes in the retail environment, the Company’s ability to successfully integrate newly acquired businesses, the level and pricing of future orders from the Company’s customers, the extent to which the Company’s business is concentrated in a small number of customers, the Company’s dependence upon third-party suppliers, including some located in foreign countries, customer acceptance of both new designs and newly-introduced product lines, actions of competitors that may impact the Company’s business, disruptions to transportation systems or shipping lanes used by the Company or its suppliers, and the Company’s dependence upon licenses from third parties. Also, in regard to the Company’s dividend announced today and its history of paying dividends, the declaration of each dividend is at the discretion of the Company’s Board of Directors and the Company expressly disclaims any assurances as to the frequency and amount of any future dividends. Reference is also made to the Company’s periodic filings with the Securities and Exchange Commission for additional factors that may impact the Company’s results of operations and financial condition. The Company does not undertake to update the forward-looking statements contained herein to conform to actual results or changes in our expectations, whether as a result of new information, future events or otherwise.

Contact:

Craig J. Demarest
Vice President and Chief Financial Officer
(225) 647-9118
[email protected]

Investor Relations:

Three Part Advisors
Steven Hooser, Partner, or Matt Hodges, Managing Director
(817) 310-8776

Veteran leader in public safety, national security, and critical infrastructure protection brings strategic, operational, and innovation expertise to advance Draganfly’s public safety mission

Saskatoon, SK, May 14, 2025 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8), an industry-leading drone solutions and systems developer, is proud to announce the appointment of Peter Lambrinakos, O.O.M., CPP, to its Public Safety Advisory Board. An internationally recognized authority in public safety leadership, national security, and the responsible deployment of emerging technologies, Mr. Lambrinakos brings more than three decades of operational, strategic, and innovation experience to advance Draganfly’s next phase of growth.

Mr. Lambrinakos previously served as the inaugural Chief of Police and Chief of Corporate Security for VIA Rail Canada, where he established and led Canada’s first dedicated intercity rail police service, protecting critical transportation infrastructure across a 12,500-kilometre national network. Before his tenure at VIA Rail, Mr. Lambrinakos held senior executive leadership roles with the Montreal Police Service (SPVM), where he commanded key divisions including Major Crimes, Economic Crimes, Organized Crime, Intelligence, and Crisis Response. He spearheaded transformational public safety reforms, created the Montreal Metro Police Division for North America’s third-busiest subway system, oversaw counter-terrorism and national security initiatives, and led the development of major crisis management structures for the City of Montreal. His leadership was instrumental in advancing public safety innovation, protecting critical infrastructure, and enhancing public trust in Canada’s second-largest urban police service.

Currently, Mr. Lambrinakos serves as a Commission Member with the Military Police Complaints Commission of Canada, an independent federal body providing civilian oversight of military policing. He is also the Distinguished Fellow and Director of the Public Safety Program at the University of Ottawa’s Professional Development Institute, and Co-Founder of the IJIS Institute’s Center of Excellence on Artificial Intelligence for Justice, Public Safety, and Security, advancing ethical AI integration across public safety sectors.

A recipient of the prestigious Officer of the Order of Merit of the Police Forces (O.O.M.), Lambrinakos’s career exemplifies a steadfast dedication to innovation, operational excellence, and public trust. His appointment strengthens Draganfly’s mission to develop secure, ethical drone technologies that address the evolving needs of public safety agencies and national security stakeholders.

“Canada has long been a global leader in integrating technology into public safety operations,” said Peter Lambrinakos. “Draganfly’s commitment to responsible, secure drone innovation that supports front-line responders is critical—not only to Canada’s evolving safety landscape but to setting global standards for public protection and critical infrastructure resilience.”

Lambrinakos’s appointment comes at a pivotal time as governments and agencies increase their demand for domestically developed, secure, and non-foreign-made drone technologies that meet stringent operational and national security standards. Draganfly, proudly Canadian-founded and headquartered, is uniquely positioned to support North American and allied public safety agencies with secure, scalable solutions that align with national defence and homeland security priorities.

“We are honoured to welcome Peter to our Public Safety Advisory Board,” said Cameron Chell, CEO of Draganfly. “His track record of service and dedication to Canadian public safety is unmatched. With his guidance, Draganfly will continue to lead the way in deploying advanced, ethical drone technologies that protect communities, support law enforcement, and empower emergency response teams.”

Draganfly’s Public Safety Advisory Board brings together experienced leaders from law enforcement, emergency management, and defence sectors to guide the development and deployment of its public safety drone ecosystem. This includes situational awareness platforms, AI-enhanced aerial systems, and integrated response tools—many of which are designed, engineered, and manufactured in Canada.

With Lambrinakos’s expertise, Draganfly will continue to strengthen its position as a trusted Canadian ally in public safety, upholding the country’s legacy of innovation, integrity, and operational excellence.

For more information about Draganfly and its leadership team, visit draganfly.com.

About Draganfly

Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8) is a global leader in drone technology, AI, and autonomous systems, providing innovative solutions for public safety, defense, agriculture, and industrial applications. With over 25 years of experience, Draganfly is recognized for its groundbreaking contributions to the UAV industry and commitment to delivering cutting-edge, North American-made technology.

CSE Listing





NASDAQ Listing





Frankfurt Listing

Media Contact

Erika Racicot
Email:[email protected]

Company Contact

Email:[email protected]

— First patient expected to be dosed during Q2 2025 —
— Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and cutaneous neurofibromas —
— Starting dose of 4mg tablet QD (once daily) —
— First trial site in Australia. Four additional sites planned for Australia, South Korea, and U.S. –
— Australian R&D Tax Incentive refund of up to 48.5% of eligible study-related costs expected —

MIAMI, May 14, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor today announced initiation of its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PAS-004, in adult participants with neurofibromatosis type 1 (NF1) with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas. The study will also assess preliminary anti-tumor activity and help determine a recommended dose for subsequent Phase 2 trials. Exploratory objectives include assessing the effects of PAS-004 on cutaneous neurofibromas.

The first active clinical trial site is the Royal North Shore Hospital in Sydney, Australia, which is expected to begin patient enrollment in Q2 2025. Additional clinical trial sites in Australia, South Korea, and the United States are expected to be opened in the coming months.

Pasithea has selected Novotech (Australia) Pty Limited as its clinical research organization (CRO) for this trial. The Company is conducting the study through its wholly owned subsidiary in Australia, Pasithea MacroMEK Pty Ltd, and anticipates eligibility for an Australian R&D Tax Incentive with a cash refund of up to 48.5% of the amount spent annually on eligible R&D activities (trial costs) in Australia.

Dr. Rebecca Brown, M.D., Ph.D. a member of Pasithea’s Scientific Advisory Board and Associate Professor of Neuro Oncology at The University of Alabama at Birmingham commented, “I am pleased to have collaborated with the Pasithea team on the design of a comprehensive dose exploration and expansion study to assess the safety and tolerability of PAS-004 in adult NF1 patients. In addition to testing the effects of PAS-004 on plexiform neurofibromas, exploratory endpoints will also examine the effects of PAS-004 on cutaneous neurofibromas. The safety profile observed to date in advanced cancer patients is encouraging, and I look forward to seeing that profile translate to the NF1 population.” Dr. Brown added, “One of the biggest challenges in treating plexiform neurofibromas associated with NF1 is ensuring that patients remain on MEK inhibitor therapy over the long-term. Real-world data shows that a significant proportion of NF1 patients discontinue treatment due to poor tolerability, including high rates of rash and gastrointestinal side effects. PAS-004 is also given as a once daily dose that offers a more convenient regimen than current FDA-approved therapies that are dosed twice a day and which could improve patient compliance.”

Dr. Tiago Reis Marques, Pasithea’s Chief Executive Officer, said, “Following our recent financing, including the exercise of certain warrants, Pasithea is now funded to produce initial interim patient data in NF1. The initiation of this clinical trial in NF1, the initial indication we seek FDA marketing approval for, marks an important milestone for Pasithea and for patients living with NF1-related plexiform neurofibromas. Activating our first clinical trial site underscores our commitment to advancing PAS-004 as a potential best-in-class next-generation MEK inhibitor. We are encouraged by the safety and clinical data observed to date in oncology patients and are optimistic that PAS-004’s tolerability profile will extend to the NF1 population. Importantly, our existing cancer data has enabled us to begin the NF1 trial at a higher dose than originally contemplated. In addition, we anticipate meaningful cash rebates of eligible trial costs through the Australian R&D Tax Incentive, further enhancing the efficiency of this program.”

About the Phase 1/1b Clinical Trial in Adult NF1 Patients

The primary objective of the Phase 1/1b study (NCT06961565) is to evaluate the safety and tolerability of PAS-004 when administered for one 28-day treatment cycle in adult NF1 participants with at least one and up to two additional target plexiform neurofibromas (PNs) that are symptomatic and inoperable, incompletely resected, or recurrent. Secondary objectives are (i) to identify the recommended Part B dose (“RPBD”) or Maximum Tolerated Dose (MTD) of PAS-004, (ii) to characterize the PK and PD profile of PAS-004, (iii) to evaluate the preliminary efficacy of PAS-004 on target PN volume, (iv) to evaluate the preliminary efficacy of PAS-004 on the size, appearance, and associated symptoms of cutaneous neurofibromas (CNs), and (v) to evaluate the impact of PAS-004 on quality of life (“QOL”) and any physical symptoms attributed to the target PN. Experimental objectives are (i) to evaluate the impact of PAS-004 on QOL and any physical symptoms attributed to CNs, (ii) to evaluate the impact of PAS-004 on pain and function attributed to PNs, and (iii) to investigate PAS-004 effects on CN tumor cellular and molecular biology.

The trial will be conducted in two parts. In Part A, following a screening period of up to 28 days, up to 24 eligible participants will be enrolled sequentially to receive one of four planned dose levels of PAS-004 tablets (4mg, 8mg, 12 mg, 18mg) in a modified 3+3 design. Part A will identify the recommended RPBD. During Part B, up to 24 eligible participants will be enrolled in parallel to receive one of two planned dose levels of PAS-004 tablets. Participants will be dosed at the RPBD level and at a dose level below the RPBD for up to six continuous 28-day treatment cycles. Part B will identify the recommended phase 2 dose (RP2D).

The study is planned to be conducted at five clinical trial sites in Australia, South Korea and the U.S.

To learn more about the PAS-004 clinical trial in adults with NF1-associated plexiform neurofibromas, please visit www.clinicaltrials.gov.

About Pasithea Therapeutics Corp.

Pasithea is a clinical-stage biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, RASopathies and MAPK pathway driven tumors.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company’s Phase 1/1b clinical trial of PAS-004 in adult patients with NF1-associated plexiform neurofibromas, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Pasithea Therapeutics Contact

Patrick Gaynes
Corporate Communications
[email protected]

QUEBEC CITY, Canada, May 14, 2025 (GLOBE NEWSWIRE) — LeddarTech^® Holdings Inc. (“LeddarTech”) (Nasdaq: LDTC), an AI-powered software company recognized for its innovation in advanced driver assistance systems (ADAS) and autonomous driving (AD), is pleased to announce the launch of LeddarSim™, a next-generation simulation platform purposely built to reduce the gap between virtual testing and real-world deployment.

LeddarSim redefines the standards of ADAS and AD development by closing the long-standing simulation gap through delivering a breakthrough multi-modality neural reconstruction of driving scenarios, including camera, radar and LiDAR inputs. The platform generates sensor-accurate, real-time renderings of real-world driving, resulting in a high-fidelity environment that empowers developers to train, test and validate perception models under conditions that mirror real-life complexity and dynamics.

Anticipated Benefits to Automotive OEMs and Tier 1 Suppliers:

• Accelerate Time-to-Market: LeddarSim allows ADAS/AD engineers to reconstruct and test millions of configurable scenarios virtually, significantly reducing development cycles and speeding up validation.
• Cut Costs, Not Corners: LeddarSim offers a cost-effective solution without compromising accuracy, leading to a 10x reduction in data and annotation costs and significant savings in non-recurring engineering (NRE) expenses.
• Design Once, Deploy Anywhere: LeddarSim’s flexibility allows for easy adaptation of sensor setups, vehicle types and regional driving conditions, enabling scalable development across various platforms.
• Data-Driven Simulation: Unlike synthetic environments, LeddarSim builds realistic scenarios directly from real-world data, enhancing the accuracy and relevance of simulations.
• Multi-Modal Sensor Support: LeddarSim can simulate data from cameras, radar and LiDAR simultaneously, optimizing and validating multi-sensor perception systems.
• Near-Zero Simulation Gap: LeddarSim uses advanced AI algorithms ensuring fidelity to real-world conditions; this comprehensive approach minimizes the gap between virtual testing and real-world performance.

“Traditional simulation platforms struggle to match the unpredictability and nuance of real-world driving,” said Pierre Olivier, CTO of LeddarTech. “With LeddarSim, we’ve managed to design a solution that achieves a near-zero simulation gap. By accelerating testing and validation cycles, LeddarSim empowers automotive OEMs and Tier 1 suppliers to bring next-generation ADAS and autonomous driving solutions to market faster, with greater confidence in performance and safety.”

Antonio Polo, Sr. Vice-President of Product and Business Development at LeddarTech, added: “Automotive companies face exponential challenges in the cost, complexity and scale of the data required to deploy safety-compliant and regulation-ready ADAS and AD systems at scale. LeddarSim brings the latest advances in AI-powered, multi-modal sensor dataset generation to recreate real-world driving scenarios with high fidelity. We believe LeddarSim fills a critical gap in the market. As the demand for simulation tools grows—with the industry expected to surpass $4.6 billion by 2035—this solution is poised to help address the massive data and validation challenge. LeddarSim is available for trial evaluation and offers the flexibility to be used as a stand-alone tool or integrated within existing simulation toolchains.”

For more information on LeddarSim™, please contact us or visit the LeddarSim page.

About LeddarTech

A global software company founded in 2007 and headquartered in Quebec City with additional R&D centers in Montreal and Tel Aviv, Israel, LeddarTech develops and provides comprehensive AI-based low-level sensor fusion and perception software solutions that enable the deployment of ADAS, autonomous driving (AD) and parking applications. LeddarTech’s automotive-grade software applies advanced AI and computer vision algorithms to generate accurate 3D models of the environment to achieve better decision making and safer navigation. This high-performance, scalable, cost-effective technology is available to OEMs and Tier 1-2 suppliers to efficiently implement automotive and off-road vehicle ADAS solutions.

LeddarTech is responsible for several remote-sensing innovations, with over 190 patent applications (112 granted) that enhance ADAS, AD and parking capabilities. Better awareness around the vehicle is critical in making global mobility safer, more efficient, sustainable and affordable: this is what drives LeddarTech to seek to become the most widely adopted sensor fusion and perception software solution.

LeddarTech might, in the scope of collaborations, partnerships and projects, from time to time, collect with test vehicles personal information, i.e., information that directly or indirectly identifies members of the public. Collected personal information may be processed, used, stored and communicated by LeddarTech within the scope of developing and training our software and products. For further information about the processing activities, which include the collection, use, storage and communication of personal information, as well as the associated personal information protection rights and how to exercise them, please consult LeddarTech’s Privacy Policy.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter (X), Facebook and YouTube.

Forward-Looking Statements

Certain statements contained in this Press Release may be considered forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which forward-looking statements also include forward-looking statements and forward-looking information within the meaning of applicable Canadian securities laws), including, but not limited to, statements relating to LeddarTech’s anticipated strategy, future operations, prospects, objectives and financial projections and other financial metrics, as well as expectations regarding the anticipated performance, adoption and commercialization of its products. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (i) our ability to timely access sufficient capital and financing on favorable terms or at all; (ii) our ability to maintain compliance with our debt covenants, including our ability to enter into any forbearance agreements, waivers or amendments with, or obtain other relief from, our lenders as needed; (iii) our ability to execute on our business model, achieve design wins and generate meaningful revenue; (iv) our ability to successfully scale and commercialize our product offerings, including through strategic collaborations or otherwise; (v) delays or cost overruns in product development, testing, validation or release; (vi) the potential for limitations in simulation fidelity, coverage or performance when compared to real-world datasets or field testing; (vii) our ability to obtain, meet and maintain the evolving technical, regulatory or safety requirements applicable to simulation tools used in regulated or performance-critical domains, such as automotive applications; (viii) customer hesitancy or delays in adoption due to integration challenges, concerns about validation equivalency or compatibility with customer workflows, data formats or toolchains; (ix) the potential for claims of intellectual property infringement or legal exposure related to simulation models, datasets or output reproducibility; (x) changes in our strategy, future operations, financial position, estimated revenues and losses, projected costs and plans; (xi) changes in general economic and/or industry-specific conditions; (xii) our ability to retain, attract and hire key personnel; (xiii) potential adverse changes to relationships with our customers, employees, suppliers or other parties; (xiv) legislative, regulatory and economic developments; (xv) the outcome of any known and unknown litigation and regulatory proceedings; (xvi) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism, outbreak of war or hostilities and any epidemic, pandemic or disease outbreak, as well as management’s response to any of the aforementioned factors; and (xvii) other risk factors as detailed from time to time in LeddarTech’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including the risk factors contained in LeddarTech’s Form 20-F filed with the SEC. The foregoing list of important factors is not exhaustive. Except as required by applicable law, LeddarTech does not undertake any obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Maram Fityani, Media and Public Relations, LeddarTech Holdings Inc.
Tel.: + 1-418-653-9000 ext. 623, [email protected]

• Investor relations website:
  investors.leddartech.com
• Investor relations contact: Mike Bishop, [email protected]

Leddar, LeddarTech, LeddarVision, LeddarSP, VAYADrive, VayaVision and related logos are trademarks or registered trademarks of LeddarTech Holdings Inc. and its subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

LeddarTech Holdings Inc. is a public company listed on the Nasdaq under the ticker symbol “LDTC.”